2024
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER
Abdin A, Kondo T, Böhm M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Desai A, Køber L, Sabatine M, Petersson M, Bachus E, Solomon S, McMurray J, Committees and Investigators O. Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 1952-1963. PMID: 39016033, DOI: 10.1002/ejhf.3350.Peer-Reviewed Original ResearchLeft ventricular ejection fractionSpectrum of left ventricular ejection fractionEffects of dapagliflozinProlongation of QRS durationVentricular ejection fractionQRS durationEjection fractionDAPA-HFHeart failurePrimary outcomeHF phenotypesPrimary composite outcome of cardiovascular deathMedian follow-up timeComposite outcome of cardiovascular deathOutcome of cardiovascular deathAssociated with worse outcomesReduced ejection fractionCardiac resynchronization therapyFollow-up timePrimary composite outcomeFavorable ventricular remodelingWorsening HFResynchronization therapyPharmacological therapyVentricular remodeling
2005
Oral Agents for Type 2 Diabetes: An Update
Kimmel B, Inzucchi S. Oral Agents for Type 2 Diabetes: An Update. Clinical Diabetes 2005, 23: 64-76. DOI: 10.2337/diaclin.23.2.64.Peer-Reviewed Original ResearchOral pharmacological therapyType 2 diabetesOptimal metabolic controlClinical trial dataRational therapeutic strategiesMechanism of actionOral agentsPharmacological therapyNonglycemic effectsCommon conditionTherapeutic strategiesDrug categoriesMetabolic controlType 2Trial dataDiabetesPatientsTherapyProper use